Bruce J Roth
Overview
Explore the profile of Bruce J Roth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1957
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morris M, Heller G, Hillman D, Bobek O, Ryan C, Antonarakis E, et al.
J Clin Oncol
. 2023 Mar;
41(18):3352-3362.
PMID: 36996380
Purpose: Enzalutamide and abiraterone both target androgen receptor signaling but via different mechanisms. The mechanism of action of one drug may counteract the resistance pathways of the other. We sought...
2.
Agarwal N, Tangen C, Hussain M, Gupta S, Plets M, Lara P, et al.
J Clin Oncol
. 2022 Apr;
40(28):3301-3309.
PMID: 35446628
Purpose: Orteronel (TAK-700) is a nonsteroidal 17,20-lyase inhibitor suppressing androgen synthesis. We evaluated the clinical benefit of orteronel when added to androgen deprivation therapy (ADT) in patients with newly diagnosed...
3.
Pedersen K, Grierson P, Picus J, Lockhart A, Roth B, Liu J, et al.
Invest New Drugs
. 2021 Mar;
39(5):1298-1305.
PMID: 33738668
Background Anti-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) combined with mTOR inhibitors, like everolimus, result in significant responses and prolonged progression-free survival (PFS) among patients with renal...
4.
Fischer-Valuck B, Michalski J, Harton J, Birtle A, Christodouleas J, Efstathiou J, et al.
Clin Genitourin Cancer
. 2020 Nov;
19(1):41-46.e1.
PMID: 33187904
Introduction: During the coronavirus disease 2019 (COVID-19) pandemic, providers and patients must engage in shared decision making to ensure that the benefit of early intervention for muscle-invasive bladder cancer exceeds...
5.
Roth B
Urol Clin North Am
. 2019 Jul;
46(3):353-362.
PMID: 31277730
Experience demonstrates multiple paths to cure for patients with clinical stage I testicular cancer. Because all options should provide a long-term disease-free rate near 100%, overall survival is no longer...
6.
Fischer-Valuck B, Michalski J, Mitra N, Christodouleas J, DeWees T, Kim E, et al.
Cancer Med
. 2019 May;
8(8):3698-3709.
PMID: 31119885
Background: Local-regional failure (LF) for locally advanced bladder cancer (LABC) after radical cystectomy (RC) is common even with chemotherapy and is associated with high morbidity/mortality. Postoperative radiotherapy (PORT) can reduce...
7.
Fischer-Valuck B, Michalski J, Contreras J, Brenneman R, Christodouleas J, Abraham C, et al.
Clin Transl Radiat Oncol
. 2019 Jan;
15:38-41.
PMID: 30656221
Introduction: Squamous cell carcinoma (SqCC) is the second most common histology of primary bladder cancer, but still very limited information is known about its treatment outcomes. Most bladder cancer trials...
8.
Cella D, Escudier B, Tannir N, Powles T, Donskov F, Peltola K, et al.
J Clin Oncol
. 2018 Jan;
36(8):757-764.
PMID: 29377755
Purpose In the phase III METEOR trial ( ClinicalTrials.gov identifier: NCT01865747), 658 previously treated patients with advanced renal cell carcinoma were randomly assigned 1:1 to receive cabozantinib or everolimus. The...
9.
Wong Y, Manola J, Hudes G, Roth B, Moul J, Barsevick A, et al.
Clin Genitourin Cancer
. 2017 Nov;
16(2):e315-e322.
PMID: 29173976
Introduction: This multicenter phase 2 study assessed the combination of estramustine and weekly paclitaxel with metastatic castration-resistant prostate cancer (CRPC). Patients And Methods: We enrolled 77 patients who had received...
10.
Tandstad T, Kollmannsberger C, Roth B, Jeldres C, Gillessen S, Fizazi K, et al.
J Clin Oncol
. 2017 Aug;
35(31):3525-3528.
PMID: 28854068
No abstract available.